Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib

Inhibitors that bind competitively to the ATP binding pocket in the kinase domain of the oncogenic fusion protein BCR–Abl1 are used successfully in targeted therapy of chronic myeloid leukemia (CML). Such inhibitors provided the first proof of concept that kinase inhibition can succeed in a clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Oruganti, Baswanth, Lindahl, Erik, Yang, Jingmei, Amiri, Wahid, Rahimullah, Rezwan, Friedman, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386466/
https://www.ncbi.nlm.nih.gov/pubmed/35809644
http://dx.doi.org/10.1016/j.jbc.2022.102238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386466/
https://www.ncbi.nlm.nih.gov/pubmed/35809644
http://dx.doi.org/10.1016/j.jbc.2022.102238

Ejemplares similares